AstraZeneca and Daiichi's Datroway offered significant improvements to overall survival (OS) in immunotherapy-ineligible patients.
(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.) Tracy Roof, University of Richmond (THE CONVERSATION) The Trump administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback